Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)
about
Factor VIIa interaction with endothelial cells and endothelial cell protein C receptor.Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancyRecombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patientsThe endothelial protein C receptor supports tissue factor ternary coagulation initiation complex signaling through protease-activated receptors.Role of tissue factor in Mycobacterium tuberculosis-induced inflammation and disease pathogenesis.Rab GTPases regulate endothelial cell protein C receptor-mediated endocytosis and trafficking of factor VIIaFactor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection.Inactivation of factor VIIa by antithrombin in vitro, ex vivo and in vivo: role of tissue factor and endothelial cell protein C receptor.FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.rFVIIa transported from the blood stream into tissues is functionally active.Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibodyEndothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa.Heterozygous congenital Factor VII deficiency with the 9729del4 mutation, associated with severe spontaneous intracranial bleeding in an adolescent maleMechanisms of anticoagulant and cytoprotective actions of the protein C pathway.Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog.Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.When should prophylaxis therapy in inhibitor patients be considered?Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients.One amino acid in mouse activated factor VII defines its endothelial protein C receptor (EPCR) binding and modulates its EPCR-dependent hemostatic activity in vivo.Endothelial protein C receptor is required for tissue factor ternary complex signaling in the mouse.Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.Redistribution and hemostatic action of recombinant activated factor VII associated with platelets.Progressive improvement in wound healing with increased therapy in haemophilia B mice.In vitro uptake of recombinant factor VIIa by megakaryocytes with subsequent production of platelets containing functionally active drug.Inhibitor development after liver transplantation in congenital factor VII deficiency.Characterization of canine coagulation factor VII and its complex formation with tissue factor: canine-human cross-species compatibility.Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia.Optimizing joint function: new knowledge and novel tools and treatments.Factor VIIa binding to endothelial cell protein C receptor: differences between mouse and human systems.
P2860
Q33729380-28FA4618-D9E5-42A6-9CAD-84FB394361D3Q34200694-F4926855-69AF-42DB-B4FD-B754E9C5B918Q34249813-B271D96E-8F0C-402B-870D-1DE27AB5D370Q34538372-8A991398-B877-4272-9880-78E162C30FEEQ34568612-893E45BC-58CA-4F63-ACA3-973D07F4A5EBQ34612375-B5349F39-BEDA-4586-B562-902196C25B04Q34648964-C17E61E5-BE00-4F96-8887-431BF3223348Q34707273-328F00B7-F474-47D7-948D-A7530BB3AD37Q35221091-6DC43F28-254F-4B3D-AA6B-06C76E7C1448Q35612397-240479C9-A968-4D81-A7F2-4B8F484C125DQ35755627-51751466-53C1-4F2E-A881-7F4AF1FCB1DAQ36222474-BC4361DE-BADD-436E-9113-A1DCD89ED2D3Q36484525-80B82425-7CD0-4CFA-9824-10953558199EQ36921588-18DB141D-560D-4A44-8590-763B041E94F2Q37019583-592ABE79-F2AA-4331-A55C-07A2C5D6AAB8Q37586365-22AE65D4-D367-4369-8C2A-8F5F68C608EBQ37778292-9D4BFEEC-4732-4C4A-A7B2-CAFC64346026Q37854874-F9034AEA-FB02-4CDE-9DC4-3EC35DBBBDDCQ38546790-93B846F2-F490-4E99-B610-4E4C8AD7081AQ39051233-2BD339CA-A504-4C6D-9A77-556FD7E94BECQ39540209-623AB8C1-2329-4B41-B8C8-0BE33D370D12Q39591239-8F468E85-E9BC-4536-9034-C38B135EFB25Q42112270-29747FA1-A7B0-46BA-8F31-F763CA853069Q44088511-03D9C123-09DC-4303-80E2-A339033264CEQ45855083-161F9B6D-6E2B-4874-A005-B4E561610A6EQ45857215-A5D939B3-61C2-4B49-BC52-1070EFBC11AAQ45859525-7E0CC676-10D1-4726-9307-540C018449FEQ45880167-427CFD0F-693C-466A-B25A-148A9C4003FFQ45880179-EDD6E642-180A-4368-9843-C4124A1AA6DFQ54949660-70823AA7-E535-4001-90C9-FDF2AC5541A5
P2860
Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)
@ast
Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)
@en
type
label
Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)
@ast
Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)
@en
prefLabel
Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)
@ast
Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)
@en
P2093
P2860
P1476
Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)
@en
P2093
P2860
P304
P356
10.1111/J.1538-7836.2009.03696.X
P577
2009-11-23T00:00:00Z